"Patient"

We all know that we need to pay attention to our diet after suffering from a disease, because improper diet will affect the recovery of the disease and the health of the patient.

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.

Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.

The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!

The European Union has recently approved Roctavian, the first gene therapy for haemophilia A. The therapy has led to a significant reduction in the average number of annual bleeds and the average number of annual clotting factor VIII transfusions in patients with this severe bleeding disorder, and has a good safety profile.

The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.